Brii Biosciences Limited
BRIBF
$0.2406
$0.00944.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 44.00K | 89.10K |
| Total Other Revenue | 6.94M | 6.11M | 5.26M | 6.54M | 7.89M |
| Total Revenue | 6.94M | 6.11M | 5.26M | 6.59M | 7.98M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.94M | 6.11M | 5.26M | 6.59M | 7.98M |
| SG&A Expenses | 28.35M | 28.42M | 28.44M | 28.17M | 28.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.08M | 68.44M | 73.66M | 79.11M | 84.94M |
| Operating Income | -56.14M | -62.33M | -68.41M | -72.52M | -76.97M |
| Income Before Tax | -71.21M | -54.42M | -37.56M | -32.05M | -26.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.21 | -54.42 | -37.56 | -32.05 | -26.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 586.10K | 663.00K | 738.80K | 1.05M | 1.36M |
| Net Income | -70.63M | -53.76M | -36.82M | -31.00M | -25.34M |
| EBIT | -56.14M | -62.33M | -68.41M | -72.52M | -76.97M |
| EBITDA | -55.63M | -61.74M | -67.75M | -71.73M | -76.03M |
| EPS Basic | -0.10 | -0.07 | -0.05 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.10 | -0.07 | -0.05 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 2.92B | 2.92B | 2.92B | 2.91B | 2.91B |
| Average Diluted Shares Outstanding | 2.92B | 2.92B | 2.92B | 2.91B | 2.91B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |